Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models.

The present study was performed in an attempt to develop an in vitro integrated testing strategy (ITS) to evaluate drug-induced neurotoxicity. A number of endpoints were analyzed using two complementary brain cell culture models and an in vitro blood-brain barrier (BBB) model after single and repeated exposure treatments with selected drugs that covered the major biological, pharmacological and neuro-toxicological responses. Furthermore, four drugs (diazepam, cyclosporine A, chlorpromazine and amiodarone) were tested more in depth as representatives of different classes of neurotoxicants, inducing toxicity through different pathways of toxicity. The developed in vitro BBB model allowed detection of toxic effects at the level of BBB and evaluation of drug transport through the barrier for predicting free brain concentrations of the studied drugs. The measurement of neuronal electrical activity was found to be a sensitive tool to predict the neuroactivity and neurotoxicity of drugs after acute exposure. The histotypic 3D re-aggregating brain cell cultures, containing all brain cell types, were found to be well suited for OMICs analyses after both acute and long term treatment. The obtained data suggest that an in vitro ITS based on the information obtained from BBB studies and combined with metabolomics, proteomics and neuronal electrical activity measurements performed in stable in vitro neuronal cell culture systems, has high potential to improve current in vitro drug-induced neurotoxicity evaluation.

[1]  Leonora Buzanska,et al.  Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals. , 2011, ALTEX.

[2]  Dieter G Weiss,et al.  Amiodarone biokinetics, the formation of its major oxidative metabolite and neurotoxicity after acute and repeated exposure of brain cell cultures. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  A. Leenhardt,et al.  Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. , 2009, British journal of clinical pharmacology.

[4]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[5]  U. Bredberg,et al.  In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids , 2007, Drug Metabolism and Disposition.

[6]  Knut Reinert,et al.  OpenMS – An open-source software framework for mass spectrometry , 2008, BMC Bioinformatics.

[7]  Edwin R. Chapman,et al.  Synaptotagmin: A Ca2+ sensor that triggers exocytosis? , 2002, Nature Reviews Molecular Cell Biology.

[8]  Bas J Blaauboer,et al.  Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. , 2013, Journal of proteomics.

[9]  G. Gross,et al.  Stimulation of monolayer networks in culture through thin-film indium-tin oxide recording electrodes , 1993, Journal of Neuroscience Methods.

[10]  Thomas Hartung,et al.  Integrated Testing Strategies (ITS) for safety assessment. , 2015, ALTEX.

[11]  R. Cecchelli,et al.  In vitro blood–brain barrier model adapted to repeated dose toxicological screening , 2011 .

[12]  Maxime Culot,et al.  A Stable and Reproducible Human Blood-Brain Barrier Model Derived from Hematopoietic Stem Cells , 2014, PloS one.

[13]  Mardas Daneshian,et al.  Consensus report on the future of animal-free systemic toxicity testing. , 2014, ALTEX.

[14]  Ralf Regenthal,et al.  Drug Levels: Therapeutic and Toxic Serum/Plasma Concentrations of Common Drugs , 1999, Journal of Clinical Monitoring and Computing.

[15]  Dieter G Weiss,et al.  Acute functional neurotoxicity of lanthanum(III) in primary cortical networks. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  M. Cleves,et al.  Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism. , 2006, Birth defects research. Part A, Clinical and molecular teratology.

[17]  C. Laggner,et al.  Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.

[18]  P G Nelson,et al.  Mouse spinal cord in cell culture. I. Morphology and intrinsic neuronal electrophysiologic properties. , 1977, Journal of neurophysiology.

[19]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.

[20]  Thomas Hartung,et al.  Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. , 2013, ALTEX.

[21]  M. Zurich,et al.  Ochratoxin A at nanomolar concentration perturbs the homeostasis of neural stem cells in highly differentiated but not in immature three-dimensional brain cell cultures. , 2011, Toxicology letters.

[22]  F. Pistollato,et al.  Standardization of pluripotent stem cell cultures for toxicity testing , 2012, Expert opinion on drug metabolism & toxicology.

[23]  R. Baughman,et al.  Primary culture of identified neurons from the visual cortex of postnatal rats , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  D. Weiss.  Neurotoxicity Assessment by Recording Electrical Activity from Neuronal Networks on Microelectrode Array Neurochips , 2011 .

[25]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[26]  Brigitte Landesmann,et al.  Adverse Outcome Pathway-based Screening Strategies for an Animal-free Safety Assessment of Chemicals , 2013, Alternatives to laboratory animals : ATLA.

[27]  M. Dehouck,et al.  Bovine Brain Endothelial Cells Express Tight Junctions and Monoamine Oxidase Activity in Long‐Term Culture , 1989, Journal of neurochemistry.

[28]  H. Monyer,et al.  Aspartate neurotoxicity on cultured cortical neurons , 1989, Journal of neuroscience research.

[29]  Andrew F M Johnstone,et al.  Burst and principal components analyses of MEA data for 16 chemicals describe at least three effects classes. , 2014, Neurotoxicology.

[30]  K. Hornbuckle,et al.  Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .

[31]  Thomas Hartung,et al.  The value of alternative testing for neurotoxicity in the context of regulatory needs. , 2006, Environmental toxicology and pharmacology.

[32]  Martin Paparella,et al.  International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes , 2015, Archives of Toxicology.

[33]  P. Honegger,et al.  Growth and differentiation of aggregating fetal brain cells in a serum-free defined medium , 1979, Nature.

[34]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[35]  A. Harsch,et al.  Odor, drug and toxin analysis with neuronal networks in vitro: extracellular array recording of network responses. , 1997, Biosensors & bioelectronics.

[36]  G. Gross,et al.  Substance identification by quantitative characterization of oscillatory activity in murine spinal cord networks on microelectrode arrays , 2004, The European journal of neuroscience.

[37]  L. Fenart,et al.  In vitro model for evaluating drug transport across the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[38]  O. Langer,et al.  Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. , 2013, Journal of labelled compounds & radiopharmaceuticals.

[39]  G. Gross,et al.  Emerging Histiotypic Properties of Cultured Neuronal Networks , 2006 .

[40]  G. Gross,et al.  Complete inhibition of spontaneous activity in neuronal networks in vitro by deltamethrin and permethrin. , 2008, Neurotoxicology.

[41]  D. Weiss,et al.  Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties. , 2011, Journal of medicinal chemistry.

[42]  A. Gramowski,et al.  Nanoparticles Induce Changes of the Electrical Activity of Neuronal Networks on Microelectrode Array Neurochips , 2010, Environmental health perspectives.

[43]  R. Turnaturi,et al.  The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures , 2013, Neuropharmacology.

[44]  Karl Mechtler,et al.  General statistical modeling of data from protein relative expression isobaric tags. , 2011, Journal of proteome research.

[45]  R. Petralia,et al.  The metabotropic glutamate receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and glial localizations , 1996, Neuroscience.

[46]  M. Chiappalone,et al.  Development of Micro-Electrode Array Based Tests for Neurotoxicity: Assessment of Interlaboratory Reproducibility with Neuroactive Chemicals , 2011, Front. Neuroeng..

[47]  S. Amara,et al.  The mouse and human excitatory amino acid transporter gene (EAAT1) maps to mouse chromosome 15 and a region of syntenic homology on human chromosome 5. , 1994, Genomics.

[48]  R. Shiekhattar,et al.  A core–BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Visvikis,et al.  The changing faces of glutathione, a cellular protagonist. , 2003, Biochemical pharmacology.

[50]  H. Hogberg,et al.  Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered. , 2010, Neurotoxicology and teratology.

[51]  Andrew F M Johnstone,et al.  Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century. , 2010, Neurotoxicology.

[52]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.

[53]  Maxime Culot,et al.  New strategy for alerting central nervous system toxicity: Integration of blood-brain barrier toxicity and permeability in neurotoxicity assessment. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[54]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[55]  D. Signorini,et al.  Neural networks , 1995, The Lancet.

[56]  P Delorme,et al.  An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro , 1990, Journal of neurochemistry.

[57]  György Buzsáki,et al.  How can drug discovery for psychiatric disorders be improved? , 2007, Nature Reviews Drug Discovery.

[58]  E. Tiffany-Castiglioni,et al.  Evaluation of neurotoxic potential by use of in vitro systems , 2005, Expert opinion on drug metabolism & toxicology.

[59]  Joseph Kleinjans,et al.  Toxicogenomics-Based Cellular Models. Alternatives to Animal Testing for Safety Assessment , 2014 .

[60]  M. Dehouck,et al.  Highly purified lipoteichoic acid from gram-positive bacteria induces in vitro blood–brain barrier disruption through glia activation: Role of pro-inflammatory cytokines and nitric oxide , 2006, Neuroscience.

[61]  S. Bryant,et al.  Open mass spectrometry search algorithm. , 2004, Journal of proteome research.

[62]  Ronald J Moore,et al.  Development and evaluation of a micro- and nanoscale proteomic sample preparation method. , 2005, Journal of proteome research.

[63]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[64]  J. Cooper,et al.  Molecular sieving characteristics of the cultured endothelial monolayer , 1987, Journal of cellular physiology.

[65]  Dieter G Weiss,et al.  Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips , 2006, The European journal of neuroscience.

[66]  D. Weiss,et al.  Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood-brain barrier. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[67]  P. West,et al.  Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. , 2010, Toxicology and applied pharmacology.

[68]  Alexander Amberg,et al.  Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[69]  Philippe Grandjean,et al.  Advancing the science of developmental neurotoxicity (DNT): testing for better safety evaluation. , 2012, ALTEX.

[70]  Timothy J Shafer,et al.  Evaluation of microelectrode array data using Bayesian modeling as an approach to screening and prioritization for neurotoxicity testing. , 2013, Neurotoxicology.

[71]  L. Smirnova,et al.  Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities. , 2014, ALTEX.

[72]  Antonio Novellino,et al.  Feasibility Assessment of Micro-Electrode Chip Assay as a Method of Detecting Neurotoxicity in vitro , 2011, Front. Neuroeng..

[73]  Timothy J Shafer,et al.  Multi-well microelectrode array recordings detect neuroactivity of ToxCast compounds. , 2014, Neurotoxicology.

[74]  J. Booher,et al.  Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. , 1972, Neurobiology.

[75]  M. Zurich,et al.  Preparation and Use of Serum-Free Aggregating Brain Cell Cultures for Routine Neurotoxicity Screening , 2011 .

[76]  M. Zurich,et al.  Neurotoxicant-induced inflammatory response in three-dimensional brain cell cultures , 2007, Human & experimental toxicology.

[77]  A. Davison.  Basic Neurochemistry: Molecular, Cellular, and Medical Aspects , 1989 .

[78]  S. Platt,et al.  The role of glutamate in central nervous system health and disease--a review. , 2007, Veterinary journal.

[79]  Michela Chiappalone,et al.  Cortical cultures coupled to micro-electrode arrays: a novel approach to perform in vitro excitotoxicity testing. , 2012, Neurotoxicology and teratology.

[80]  P. Molinoff,et al.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .

[81]  M Culot,et al.  In vitro blood-brain barrier model adapted to repeated-dose toxicological screening. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[82]  O. Kohlbacher,et al.  Probabilistic consensus scoring improves tandem mass spectrometry peptide identification. , 2011, Journal of proteome research.

[83]  D. Choi,et al.  Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay , 1987, Journal of Neuroscience Methods.

[84]  T. Minami,et al.  Toxicity of cisplatin to the central nervous system of male rabbits , 2000, Biological Trace Element Research.

[85]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[86]  Andrew Worth,et al.  Metabolism: A Bottleneck in In Vitro Toxicological Test Development , 2006, Alternatives to laboratory animals : ATLA.

[87]  Maxime Culot,et al.  An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[88]  R. Szargel,et al.  Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Joshua A. Harrill,et al.  In Vitro Assessment of Developmental Neurotoxicity: Use of Microelectrode Arrays to Measure Functional Changes in Neuronal Network Ontogeny1 , 2010, Front. Neuroeng..

[90]  R. Cecchelli,et al.  A Simple Method for Assessing Free Brain/Free Plasma Ratios Using an In Vitro Model of the Blood Brain Barrier , 2013, PloS one.

[91]  G. Gross,et al.  NMDA receptor-dependent periodic oscillations in cultured spinal cord networks. , 2001, Journal of neurophysiology.

[92]  D. McCormick,et al.  Essential Role of Phosphoinositide Metabolism in Synaptic Vesicle Recycling , 1999, Cell.

[93]  Alf Lamprecht,et al.  Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution , 2014, Drug Metabolism and Disposition.

[94]  B. Meldrum,et al.  Glutamate as a neurotransmitter in the brain: review of physiology and pathology. , 2000, The Journal of nutrition.

[95]  T. Hartung,et al.  A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. , 2008, Neurotoxicology.

[96]  Xingrong Liu,et al.  EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION , 2006, Drug Metabolism and Disposition.

[97]  J. Sweedler,et al.  Qualitative and quantitative metabolomic investigation of single neurons by capillary electrophoresis electrospray ionization mass spectrometry , 2013, Nature Protocols.

[98]  S A Kuznetsov,et al.  The interaction between cytoplasmic dynein and dynactin is required for fast axonal transport. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[100]  P. Hof,et al.  Amyloid precursor protein (APP) regulates synaptic structure and function , 2012, Molecular and Cellular Neuroscience.

[101]  Perinatal Manganese Exposure and Hydroxyl Radical Formation in Rat Brain , 2014, Neurotoxicity Research.

[102]  A. Kopp-Schneider,et al.  Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[103]  M. Diksic,et al.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats , 2005, Journal of Neuro-Oncology.

[104]  K. Crofton,et al.  Putative adverse outcome pathways relevant to neurotoxicity , 2015, Critical reviews in toxicology.

[105]  Antonio Novellino,et al.  Application of micro-electrode arrays (MEAs) as an emerging technology for developmental neurotoxicity: evaluation of domoic acid-induced effects in primary cultures of rat cortical neurons. , 2011, Neurotoxicology.

[106]  Guy C. Brown,et al.  Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibiting Neuronal Respiration, Causing Glutamate Release and Excitotoxicity , 2001, The Journal of Neuroscience.

[107]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[108]  C. Harris,et al.  Altered differentiation in rat and rabbit limb bud micromass cultures by glutathione modulating agents. , 2001, Free radical biology & medicine.

[109]  Timothy J Shafer,et al.  Evaluation of multi-well microelectrode arrays for neurotoxicity screening using a chemical training set. , 2012, Neurotoxicology.

[110]  D J Dix,et al.  Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. , 2011, Toxicology and applied pharmacology.

[111]  T. Südhof,et al.  Activity-Dependent IGF-1 Exocytosis Is Controlled by the Ca 2+ -Sensor , 2011 .